In summary, loratadine combined with intranasal mometasone furoate achieved marked symptom relief (nasal obstruction: 7.32→1.46 points; runny nose: 7.79→1.09 points) and reduced inflammatory biomarkers (IgE: 421.29→117.29 U/mL; IL-6: 10.37→5.18 ng/mL) in AR patients, with a favorable safety profile (NNT = 9; adverse reaction rate = 8.62%). The gene discussed is IL6; the disease is Nasal congestion.